Cargando…

Galunisertib enhances chimeric antigen receptor-modified T cell function

Chimeric antigen receptor (CAR) T cell therapy still faces the challenge of immunosuppression when treating solid tumors. TGF-β is one of the critical factors in the tumor microenvironment to help tumors escape surveillance by the immune system. Here we tried using the combination of a small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhixiong, Liu, Qian, Risu, Na, Fu, Jiayu, Zou, Yan, Tang, Jiaxing, Li, Long, Liu, Hui, Zhou, Guomin, Zhu, Xuekai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388644/ https://www.ncbi.nlm.nih.gov/pubmed/32705856 http://dx.doi.org/10.4081/ejh.2020.3122

Ejemplares similares

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
por: Tang, Jiaxing, et al.
Publicado: (2021)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Research advances in chimeric antigen receptor-modified T-cell therapy (Review)
por: Luo, Yuxi, et al.
Publicado: (2021)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
por: Yan, Lingli, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018)

Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma
por: Zhao, Lei, et al.
Publicado: (2020)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Design of Gelatin-Capped Plasmonic-Diatomite Nanoparticles with Enhanced Galunisertib Loading Capacity for Drug Delivery Applications
por: Tramontano, Chiara, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017)

Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial Involvement
por: Han, Brian, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
por: Liu, X., et al.
Publicado: (2016)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression
por: Rani, Bhavna, et al.
Publicado: (2018)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells
por: Hale, Malika, et al.
Publicado: (2017)

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
por: Neeser, A., et al.
Publicado: (2023)

Metformin inhibits proliferation and cytotoxicity and induces apoptosis via AMPK pathway in CD19-chimeric antigen receptor-modified T cells
por: Mu, Qian, et al.
Publicado: (2018)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fk38ekgs12acivabnmp0o66gj0